GLP-1 Pills vs. Injections: Weight Loss Data
A new oral form of semaglutide, sold under the brand name Wegovy, is now available for weight management. This development addresses a long-standing challenge in delivering GLP-1 medications, which have historically been broken down by the digestive system before they could be fully absorbed.
Overcoming Digestive Barriers
Until recently, the stomach environment—with its acids and enzymes—prevented GLP-1 medications from effectively reaching the bloodstream. New oral formulations are specifically designed to protect these active ingredients, known as peptides, as they travel through the digestive tract.
Clinical Trial Results
Clinical trials have demonstrated that the new semaglutide pill offers benefits comparable to the injectable form of the medication. In a trial evaluating the 25 milligram (mg) pill, adults experienced an average of 13.6 percent body weight loss over 64 weeks, compared to 2.2 percent in a placebo group.
For comparison, adults receiving 2.4 mg weekly injections of semaglutide achieved an average weight loss of 14.9 percent over 68 weeks, while those in the placebo group lost 2.4 percent.
FDA Approval and Dosage
The Food and Drug Administration approved the 25 mg pill for weight management based on its similarity to the injectable version in terms of both weight loss outcomes and safety, according to W. Timothy Garvey, MD, a professor of medicine at the University of Alabama at Birmingham.
The need for a higher pill dosage stems from the limited absorption of the oral medication. Dr. Garvey explains that the amount of medication entering the bloodstream is similar for both the oral and injectable forms, despite the dosage difference.
What Could Happen Next
If these positive trends continue, healthcare providers may see increased patient adherence to GLP-1 therapy due to the convenience of an oral medication. Further research could explore optimal dosing strategies and long-term effects of the oral formulation. It is also possible that other GLP-1 medications will be developed in oral forms, expanding access to these treatments.
Frequently Asked Questions
What was the average weight loss for those taking the Wegovy pill in the clinical trial?
Adults taking 25 milligrams (mg) of the Wegovy pills lost an average of 13.6 percent of their body weight over 64 weeks.
Why is the pill dosage higher than the injection dosage?
The higher 25 mg daily pill dosage ensures enough of the drug survives the digestive process to be effective, resulting in a similar amount of medication entering the bloodstream as the 2.4 mg weekly injection.
Who approved the Wegovy pills for weight management?
The FDA approved the 25 mg pills for weight management because of how similar they were to injections in terms of weight loss and safety.
How might the availability of an oral GLP-1 medication change the conversation around weight management with your healthcare provider?